Healthcare Research Report: Therapeutic Area Market

Showing posts with label Therapeutic Area Market. Show all posts

Thursday, 5 October 2017

Global Elderly Care Services Market - Increasing Demand for Quality Life by Senior Citizens 2017-2021 Edition

ResearchMoz added Latest Research Report titled " Global Elderly Care Services Market (2017-2021 Edition) " to it's Large Report database.

Scope of the Report

The report titled Global Elderly Care Services Market (2017-2021 Edition) provides a detailed analysis of the elderly care services market with description of market sizing and growth, segmentation of market by products & services and major markets, top market players etc. The report recapitulates the factors that will be responsible for the growth in the market in the forecasted period.

The report also provides country analysis of the US, Canada, Europe and India in terms of market sizing and growth. The US and Canada (in North America) are the market leaders followed by European countries. Among Asia-Pacific countries, India has been emerged as the market leader in elder care services. In coming years, Asia-Pacific would be the key market player as the growth of ageing population is more than other nations worldwide.

Request for Sample PDF of Premium Research Report with TOC: https://www.researchmoz.us/enquiry.php?type=S&repid=1221345

Furthermore, the report also profiles key market players such as Extendicare Inc., Brookdale senior Living Inc., Kindred Healthcare Inc. and Genesis Healthcare Inc. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.

Company Coverage

Extendicare
Brookdale Senior Living Inc.
Kindred Healthcare Inc.
Genesis Healthcare Inc.

Browse more details @ https://www.researchmoz.us/global-elderly-care-services-market-2017-2021-edition-report.html

Table of Content

1. Executive Summary

2. Introduction

2.1 Elderly Care Service Market: An Overview

2.1.1 Elderly Care Service: An Introduction
2.1.2 Types of Elder Care Centers
2.1.3 Category of Elderly Care Market

3. Market Analysis

3.1 Global Elderly Care Services Market: An Analysis

3.1.1 Global Elderly Care Services Market by Value
3.1.2 Global Elderly Care Services Market by Segmentation
3.1.3 Global Elderly Care Market by Technology Products
3.2 Global Home Care Services Market: An Analysis

3.2.1 Global Home Care Services Market by Value

3.2.2 Global Home Care Market by Players Type

3.3 Global Home Healthcare Market: An Analysis

3.3.1 Global Home Healthcare Market by Value
3.3.2 Global Home Healthcare Software & Services Market by Value

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Tuesday, 12 September 2017

United States Proton Therapy Market would be more than US$ 15 Billion Forecast by 2021 - Reimbursement Policy, Patients Treated at Proton Therapy Centers

ResearchMoz added Latest Research Report titled " United States Proton Therapy Market & Forecast, Reimbursement Policy, Patients Treated at Proton Therapy Centers " to it's Large Report database.

The potential market of proton therapy in United States would be more than US$ 15 Billion by the end of 2021 and it is expected to grow with a CAGR of 6.04 percent in future. At present United States holds world’s 40 percent of Proton Beam Therapy Facility. In the recent time, more research institutes and hospitals are investing in proton therapy to make the technology more accessible to patients.

United States Proton Therapy Market & Forecast, Reimbursement Policy, Patients Treated at Proton Therapy Centers is a report published by Renub Research. In this report we have studied the market in two parts a) Actual Market and b) Potential Market. The report also talks about list of all operational and future Proton Therapy centers; Economics of proton therapy including reimbursement policies. Proton Therapy revenues from 3 companies (IBA, Varian Medical Systems, Elekta) has also been studied in the report.

a) Actual Market is the current market which is already present

b) Potential Market is the market which can be achieved; but it has yet not been achieved due to demand and supply gap. At present only a few proton therapy centers are available that can treat a limited number of patients each year.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1037719

United States Proton Therapy Market has been analyzed from four view points

    United States Proton Therapy Actual Market & Forecast (2009 – 2021)
    United States Proton Therapy Untapped Market & Forecast (2009 – 2021)
    United States Proton Therapy Treated Patient Volume & Forecast (2009 – 2021)
    United States Proton Therapy Untapped Patient Volume & Forecast (2009 – 2021)

Key Companies Covered

    IBA (Overview, Sales Analysis)
    Varian Medical Systems (Overview, Sales Analysis)
    Elekta (Overview, Sales Analysis)

Table of Content

1. Executive Summary

2. United States Proton Therapy Market – Actual & Potential Market
2.1 United States – Proton Therapy Market
2.2 United States – Potential Proton Therapy Market & Forecast

Browse more details @ http://www.researchmoz.us/united-states-proton-therapy-market-forecast-reimbursement-policy-patients-treated-at-proton-therapy-centers-report.html

3. United States Proton Therapy Patient Number – Actual and Potential
3.1 United States – Patients Treated with Proton Therapy Actual Numbers & Forecast
3.2 United States – Patients with Proton Therapy Potential Numbers & Forecast

4. United States – List of Proton Therapy Centers

5. United States – Proton Therapy Treated Patients by Centers
5.1 Loma Linda (LLUMC) Proton Therapy Center – Number of Patients Treated (2008 – 2014)
5.2 UCSF – CNL Proton Therapy Center – Number of Patients Treated (2008 – 2015)
5.3 Boston (NPTC) Proton Therapy Center – Number of Patients Treated (2008 – 2015)
5.4 Bloomington (MPRI, 2) Proton Therapy Center – Number of Patients Treated (2008 – 2014)
5.5 Houston (MD Anderson) Proton Therapy Center – Number of Patients Treated (2008 – 2015)
5.6 UFPTI Jacksonville Proton Therapy Center – Number of Patients Treated (2008 – 2015)
5.7 Oklahoma City (ProCure PTC) Proton Therapy Center – Number of Patients Treated (2009 – 2015)
5.8 CDH Warrenville Proton Therapy Center – Number of Patients Treated (2010 – 2015)
5.9 Philadelphia (Upenn) Proton Therapy Center – Number of Patients Treated (2011 – 2015)
5.10 Hampton (HUPTI) Proton Therapy Center – Number of Patients Treated (2012 – 2015)
5.11 New Jersey (ProCure PTC) Proton Therapy Center – Number of Patients Treated (2012 – 2015)
5.12 Seattle (SCCA ProCure PTC) Proton Therapy Center – Number of Patients Treated (2013 – 2015)
5.13 St. Louis (S. Lee King PTC) Proton Therapy Center – Number of Patients Treated (2013 – 2015)
5.14 Provision Center for Proton Therapy, Knoxville, TN – Number of Patients Treated (2014 – 2015)
5.15 San Diego (Scripps PTC) – Number of Patients Treated (2014 – 2015)
5.16 Shreveport (Willis Knighton) Proton Therapy Center – Number of Patients Treated (2014 – 2015)

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Tuesday, 29 August 2017

Global Clear Aligner Market: Size, Trends & Forecasts 2017-2021 : Company Coverage - ClearCorrect, Align Technology, See-through Tech etc.

ResearchMoz added Latest Research Report titled " Global Clear Aligner Market: Size, Trends & Forecasts (2017-2021) " to it's Large Report database.

Scope of the Report

The report entitled Global Clear Aligner Market: Size, Trends & Forecasts (2017-2021), provides analysis of the global clear aligner market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The analysis includes the market by value, by volume and by penetration. The report also provides the analysis of the global dental market, global dental consumables market and global dental orthodontic market.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global clear aligner market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Align Technology, Inc., Dentsply International, Inc., ClearCorrect and See-through Tech, Inc. are some of the key players operating in the global clear aligner market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1273745

Company Coverage

Align Technology, Inc.
Dentsply International, Inc.
ClearCorrect
See-through Tech, Inc.

Executive Summary

A branch of medicine that includes the study, diagnosis, prevention, and treatment of disorders, diseases and conditions of the oral problem, is called Dentistry. Oral health can be defined as a state of being free from chronic mouth and facial pain, oral and throat cancer, oral sores, periodontal (gum) disease, tooth decay and tooth loss and all other diseases related to mouth. Oral health is of paramount importance, as it affects the individuals quality of life.

Browse more details @ http://www.researchmoz.us/global-clear-aligner-market-size-trends-and-forecasts-2017-2021-report.html

Table of Content

1. Executive Summary

2. Introduction

2.1 Dental Disease and Types
2.2 Dental Treatment and Types

2.2.1 Specialties
2.2.2 Prosthetics
2.2.3 Chairside Consumables

2.3 Dental Market by Segments

3. Global Market Analysis

3.1 Global Dental Market: An Analysis

3.1.1 Global Dental Market by Value
3.1.2 Global Dental Consumables Market by Value
3.1.3 Global Dental Consumables Market by Segments

3.2 Global Orthodontic Market: An Analysis

3.2.1 Global Orthodontic Market by Value
3.2.2 Global Orthodontic Market Value by Segments
3.2.3 Global Orthodontic Market by Volume
3.2.4 Global Orthodontics Market Volume by Segments

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Thursday, 24 August 2017

Global Clear Aligner Market - Size, Trends & Forecasts 2017-2021 : Company Coverage - ClearCorrect, Align Technology, See-through Tech

Global Regenerative Therapies Market to reach US$ 18,429.8 Mn by 2022, Asia Pacific & Japan to Witness Highest Growth During the Forecast Period

ResearchMoz added Latest Research Report titled " Global Market Study on Regenerative Therapies: Asia Pacific & Japan to Witness Highest Growth by 2022 " to it's Large Report database.

This Persistence Market Research (PMR) report examines the regenerative therapies market for the period 2016 - 2022. The primary objective of the report is to offer insights into developments in the regenerative therapies market that are significantly helping transform the growth trajectory of global businesses and enterprises associated with the same.

Regenerative therapies entail the application of specific types of cells or cell products for diseased tissues or organs, which ultimately help restore usual tissue and organ function. It also includes the possibility of growing tissues and organs in the laboratory and safely implanting them when the body cannot heal itself.

The regenerative therapies market holds major potential in the near future, which is attributed to the increasing application of these therapies in the treatment of various classes of diseases. The prime factor responsible for the same is the collaborative R&D efforts undertaken by researchers and manufacturers to develop and introduce newer and more efficient therapies.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1287194

Orthopedic, cardiovascular, and soft tissue repair are the three main application segments in the global regenerative therapies market. Recently, there has been an alarming rise in the incidence rate of these disorders across the globe. Soft tissue repair and skin restoration therapies are currently the most widely adopted regenerative therapies globally.

Surge in government support and funding from various organizations for R&D related to regenerative therapies over the last few years and increasing incidences of chronic diseases are among the major factors driving growth of the global regenerative therapies market currently.

The regenerative therapies market is segmented as follows:

Regenerative Therapies Market, by Tissue Type
Regenerative Therapies Market, by Application Type
Regenerative Therapies Market, by End User
Regenerative Therapies Market, by Region

Browse more details @ http://www.researchmoz.us/global-market-study-on-regenerative-therapies-asia-pacific-and-japan-to-witness-highest-growth-by-2022-report.html

Table of Content

1. Global Regenerative Therapies Market - Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Global Regenerative Therapies Market Overview
4.1. Introduction
4.1.1. Regenerative Therapies Market Definition
4.1.2. Regenerative Therapies Market Taxonomy
4.2. Regenerative Therapies Market Application Overview
4.3. Parent Market Overview
4.4. Regenerative Therapies Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.4. Value Chain
4.5. Global Regenerative Therapies Market Forecast, 2015-2021
4.5.1. Market Value Forecast
4.5.2. Y-o-Y Growth Projections
4.5.3. Absolute $ Opportunity
4.6. Regenerative Therapies Market Trends

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Monday, 5 June 2017

COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

ResearchMoz added Latest Research Report titled " COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies " to it's Large Report database.

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=938607

The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and ICS combinations, bronchodilator monotherapies and PDE-4 inhibitors. However, the market is undergoing a gradual transition, away from bronchodilator and ICS therapies and towards targeted and triple combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer greater therapeutic options.

Scope

The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%.

Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
Do branded therapies show continuous growth, and are they facing any competition from generics?
How will branded therapies be affected by upcoming pipeline therapies?

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 12
2.4.1 Pathophysiology 13
2.5 Diagnosis 13
2.6 Disease Stages 14
2.7 Prognosis 14
2.8 Treatment Options 15
2.8.1 Treatment Algorithm 16

3 Marketed Products 18
3.1 Overview 18
3.2 Bronchodilator Combination Therapy 18
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca 18
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim 20
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis 21
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance 22
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim 22

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Thursday, 1 June 2017

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

ResearchMoz added Latest Research Report titled " Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market " to it's Large Report database.

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1068037

Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.

In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 12
2.3 Symptoms 14
2.4 Etiology 15
2.5 Pathophysiology 16
2.6 Diagnosis 16
2.7 Prognosis and Disease Staging 18
2.8 Treatment Options 20
2.8.1 Surgery and Radiation Therapy 20
2.8.2 Chemotherapy 21
2.8.3 Hormonal Therapies 21
2.8.4 Targeted Therapies 22
2.9 Treatment Guidelines 23

3 Marketed Products 26
3.1 Overview 26
3.1.1 Herceptin (trastuzumab) - Genentech 27
3.1.2 Perjeta (pertuzumab) - Genentech 28
3.1.3 Afinitor (everolimus) - Novartis 29
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis 30

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Thursday, 11 May 2017

Asia Proton Therapy Market is expected to grow with a CAGR of 18% in the Forecast Period - Forecast (Japan, Korea, China) Number of Patients Treated

ResearchMoz added Latest Research Report titled " Asia Proton Therapy Market & Forecast (Japan, Korea, China) Number of Patients Treated " to it's Large Report database.

Asia Proton Therapy Market is expected to grow with a CAGR of 18 percent in the forecast period. Currently Asia has 15 proton therapy Centers, but in future this number is going to almost double as many proton therapy centers are either in under-construction phase or in planning phase. Japan has the highest market share in proton therapy market, but China and Korea are increasing their market share year on year.

Asia Proton Therapy Market & Forecast (Japan, Korea, China) Number of Patients Treated is a report published by Renub Research. This research report provides a comprehensive assessment of Proton Therapy Market in Asia, Number of Patients treated in Proton Therapy Centers in Asia and Reimbursement Policies. In this report we have studied the market in two parts a) Actual Market and b) Untapped Market.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1068124

Potential / Untapped Market is the market which can be achieved; but it has yet not been achieved due to demand and supply gap. At present only a few proton therapy centers are available that can treat a limited number of patients each year.

Key Questions Answered in the Report

Proton Therapy Market & Forecast in Asia (Japan, China, Korea)
Proton Therapy Patients & Forecast in Asia (Japan, China, Korea)
Number of Proton Therapy Centers in Asia (Japan, China, Korea)
Type of Technology being used at each Proton Therapy Centers of each country
Number of Patients treated in each Proton Therapy Centers

What is the name and number of Operational Proton Therapy Centers, Under Construction Proton Therapy Centers and Planning Stage Proton Therapy Centers in each country

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Content

1. Executive Summary

2. Asia Proton Therapy Market (Actual & Untapped)
2.1 Asia – Proton Therapy Market
2.2 Asia – Untapped Proton Therapy Market

3. Asia Proton Therapy Patient Number – Actual and Untapped
3.1 Asia – Patients Treated with Proton Therapy Actual Numbers & Forecast
3.2 Asia – Patients with Proton Therapy Untapped Numbers & Forecast

4. Asia Proton Therapy Market Share by Countries

5. Asia – List of Proton Therapy Centers
5.1 Asia Operational Proton Therapy Centers
5.2 Asia Under-Construction Proton Therapy Centers
5.3 Asia Planning Phase Proton Therapy Center

6. Asia – Proton Therapy Treated Patients by Centers (Country wise)
6.1 Japan
6.1.1 Kashiwa (NCC) Proton Therapy Center – Number of Patients Treated (2008 – 2014)
6.1.2 Hyogo (HIBMC) Proton Therapy Center – Number of Patients Treated (2008 – 2015)
6.1.3 Tsukuba (PMRC, 2) Proton Therapy Center – Number of Patients Treated (2008 – 2015)
6.1.4 WERC Proton Therapy Center – Number of Patients Treated (2008)
6.1.5 Shizuoka Proton Therapy Center – Number of Patients Treated (2008 – 2015)

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Wednesday, 3 May 2017

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

ResearchMoz added Latest Research Report titled " Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy " to it's Large Report database.

Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother.

The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to factor VIII or factor IX treatment and need a bypassing agent, such as factor VIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative market opportunity.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=879379

The current marketed products landscape comprises replacement factor therapies, such as recombinant therapies and new long-acting recombinant products. The current pipeline shows strong promise, as it shows a gradual shift from short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII, and from factor replacement therapies to non-factor therapies. Nevertheless, significant unmet need remains for products that can avoid the development of inhibitors in patients with hemophilia.

Though late-stage pipeline for treatment of hemophilia seems promising, the main market restraint is likely to be low penetration of new long-acting recombinant therapies in India and China, owing to their high expected prices.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9

2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 12
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 13
2.4.1 Hemophilia A 13
2.4.2 Hemophilia B 13
2.5 Diagnosis 14
2.6 Diagnosis of Inhibitors 14
2.7 Disease stages 15
2.8 Prognosis 15
2.9 Treatment Options 15
2.9.1 Management of Bleeding with Factor Replacement Therapy 16
2.9.2 Antifibrinolytic Medication 18
2.9.3 Treatment of Inhibitors 18
2.9.4 Gene Therapy 19
2.9.5 Hemophilia A 19
2.9.6 Hemophilia B 19

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Friday, 3 March 2017

COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

ResearchMoz added Latest Research Report titled " COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies " to it's Large Report database.

Chronic Obstructive Pulmonary Disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=938607

The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and ICS combinations, bronchodilator monotherapies and PDE-4 inhibitors. However, the market is undergoing a gradual transition, away from bronchodilator and ICS therapies and towards targeted and triple combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer greater therapeutic options.

Scope

The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%.

Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
Do branded therapies show continuous growth, and are they facing any competition from generics?
How will branded therapies be affected by upcoming pipeline therapies?

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 12
2.4.1 Pathophysiology 13
2.5 Diagnosis 13
2.6 Disease Stages 14
2.7 Prognosis 14
2.8 Treatment Options 15
2.8.1 Treatment Algorithm 16

3 Marketed Products 18
3.1 Overview 18
3.2 Bronchodilator Combination Therapy 18
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca 18
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim 20
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis 21
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance 22
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim 22
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy 23
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca 23
3.3.2 Seretide/Advair (salmeterol/fluticasone) - GlaxoSmithKline 24
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance 25

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Thursday, 16 February 2017

Malaria Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, Forecast and Opportunities 2013 - 2019

ResearchMoz added Latest Research Report titled " Malaria Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019 " to it's Large Report database.

Malaria is an infectious disease caused by plasmodium parasites that is transmitted from female anopheles mosquito.WHO stated that, malaria is one of the top public health challenge,globally. There are four species of malarial parasite that cause the disease namely,plasmodium vivax, plasmodium malariae, plasmodium ovale, and plasmodium falciparum.The incubation period for the above mentioned speciesis 1 to 60 days depending on the type of parasite. High body temperature (fever), sweat, nausea, vomiting, dry cough and muscle ache are some of the common symptoms of malaria. Diagnosis technique for detection of malaria includesmicroscope using stained thin and thick peripheral blood smears (PBS), QBC technique, and serological tests. Various kinds of drugs are utilized as a treatment option for malaria that includes artemether-lumefantrine (Coartem), atovaquone-proguanil (Malarone), chloroquine, clindamycin (used in combination with quinine), doxycycline (used in combination with quinine), mefloquine (Lariam), quinidine and quinine. In 2014,WHO published that, around207 million caseswere recorded and approximately 627,000 deathsoccurred during the year 2012.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=195822

Technological advancements in diagnostic tests and growing public awareness about the disease are the major factors driving the growth of malaria diagnostics market globally. However, technical complexities associated with existing diagnostic tests might hinder the market growth during the study period.

Geographically, RoW and Asia-Pacificdominates theglobal market for malariadiagnostics due to high prevalence rate and increased awareness among people about the disease. High death/fatality rate especially among young children is expected to propel the growth of this market in emerging economies of Asia-Pacific and Rest of the World (African countries).

Various key players contributing to the global malaria diagnostics market comprises Abbott Laboratories, Beckman Coulter/Danaher, bioMerieux, Bio-Rad Laboratories, Inc., Bio-Rad, Life Technology, Novartis Diagnostics, Ortho-Clinical Diagnostics, Siemens Healthcare and Wako Chemicals, Inc.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

    North America
    Asia Pacific
    Europe
    Rest of the World

This report provides comprehensive analysis of

    Market growth drivers
    Factors limiting market growth
    Current market trends
    Market structure
    Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a technological growth map over time to understand the industry growth rate
It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Friday, 27 January 2017

Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast 2016-2020: Key Players are Shire PLC, Kamada Ltd, Grifols SA, CSL Behring LLC

ResearchMoz added Latest Research Report titled " Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020) " to it's Large Report database.

Scope of the Report

The report titled Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020) provides an in-depth analysis of the global AAT Replacement Therapy market with detailed analysis of market sizing, growth and market share. The report provides market size by value and volume along with the supply trend prevailing in the market.

The report provides detail market analysis of the major products available in the market for treating AAT deficiency. The four major products included are, Prolastin, Glassia, Zemaira, and Aralast. Among which, Prolastin had the monopoly in the market for over 25 years, Asit was the first AAT Replacement Therapy available in the market for the treatement.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=902474

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global AAT Replacement Therapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global AAT Replacement Therapy market is stiff and dominated by the big players like Grifols. Further, key players of the AAT Replacement Therapy market, Kamada, Shire and CSL Behring are also profiled with their financial information and respective business strategies.

Regional Coverage

Global

Company Coverage

Grifols SA
Kamada Ltd.
CSL Behring LLC
Shire PLC

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Content

1. Executive Summary

2. Introduction

2.1 Introduction to Alpha-1 Antitrypsin (AAT) Deficiency
2.1.1 Impacts of AAT Deficiency
2.1.2 Diagnosis and Treatment of AAT Deficiency

2.2 AAT Replacement Therapy Overview
2.2.1 AAT Replacement Therapy
2.2.2 AAT Replacement Therapy Products

3. Global Market Analysis

3.1 Global AAT Replacement Therapy Market by Value
3.2 Global AAT Replacement Therapy Market by Volume
3.3 Global AAT Replacement Therapy Market by Product

3.3.1 Global Prolastin AAT Replacement Therapy Market by Value
3.3.2 Global Zemaira AAT Replacement Therapy Market by Value
3.3.3 Global Glassia AAT Replacement Therapy Market Analysis
Global Glassia AAT Replacement Therapy Market by Value
The U.S. Glassia AAT Replacement Therapy Prescriptions
3.3.4 Global Aralast AAT Replacement Therapy Market Analysis
Global Aralast AAT Replacement Therapy Market by Value
The U.S. Aralast AAT Replacement Therapy Prescriptions

3.4 Global AAT Replacement therapy Market Supply Trend

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Thursday, 26 January 2017

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others

ResearchMoz added Latest Research Report titled " Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others " to it's Large Report database.

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others
This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Othersevaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including

IDO (Indoleamine 2,3-dioxygenase
TDO ( Tryptophan 2,3 dioxygenase)
TGF-B/R ( Transforming Growth Factor beta/Receptor)
CXCR4(Chemokine Receptor Type 4)
CSF-1R ( Colony Stimulating Factor-1 Receptor)
CD47 SIRPa (Signal Regulatory Protein Alpha)
Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
STING (STimulator of INterferon Genes) Receptor
Others ( e.g. arginase)

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=895856

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
More than 45 new molecular entities modulating the immunosuppressive tumor microenvironment are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further eight molecules are undergoing IND-enabling studies.
The report includes a compilation of currently active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Content

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others
Table of Contents
1) IDO & TDO Inhibitors

Epacadostat Studies
Indoximod Studies
Novel IDO Inhibitors
Novel TDO Inhibitors
Dual IDO & TDO Inhibitors

2) TGF-beta/R Inhibitors
3) CXCR4 Antagonists & CXCL12 Inhibitors
4) CSF-1R Antagonists & CSF-1R tk Inhibitors
5) CD47 SIRPa Pathway Inhibition
6) Adenosine Pathway

Adenosine A2 Receptor (A2AR) Antagonists
CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation

7) STING Receptor Stimulators
8) Other Inhibitors of Immunosuppressive Tumor Microenvironment
9) Corporate Tumor Microenvironment Modulator R&D Pipelines

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Sunday, 22 January 2017

Learning Disability Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

ResearchMoz added Latest Research Report titled " Learning Disability Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020 " to it's Large Report database.

Learning disability is the disorder of brain to receive, store and respond to the new information. People suffering from learning disabilities have problems in listening, paying attention, reading, speaking, writing, reasoning and performing mathematical operations. Learning disability is actually a group of disorders, not a single disorder which includes dyslexia, dyscalculia, dysgraphia, dyspraxia, attention-deficit hyperactivity disorder (ADHD) and auditory and visual processing disorders. Learning disorders occurs at very young age but they are usually recognized at an early age of five years.

Currently there are no medicines available for the core treatment of learning disability as the cause is still unkown. However, there are few medicines available which are being prescribed for the treatment and management of ADHD disorder in patients with learning disability. These medicines are segmented into three major categories which include:

Stimulants
Non-Stimulants
Other medicines

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=209073

Stimulants are the psychoactive drugs which are focused on inducing temporary improvements in either mental or physical actions or both. These are best studied and highly used medicines to treat ADHD in learning disability treatment market. Common stimulants medications include:

Methylphenidate (Ritalin, Concerta)
Dexmethylphenidate (Focalin)
Amphetamine/Dextroamphetamine (Adderall, Dexedrine, Dextrostat)
Lisdexamfetamine (Vyvanse)

Strattera is the only non-stimulant in the learning disability market, approved by the U.S. FDA for the treatment of ADHD. Other medicines which are used for learning disability treatment include:

Antidepressants – bupropion (Wellbutrin)
Tricyclics – imipramine (Tofranil), nortriptyline (Pamelor, Aventyl), desipramine (Norpramin)
Alpha-2 agonists – clondine (Catapres), guanfacine (Tenex)

Besides, there are certain special schools which perform special kind of therapies, to manage the patient’s condition suffering from learning disability. Learning disability therapies include social skills group, solution focused counseling and cognitive behavioral therapy. Social skills group help children learn how to initiate conversations, take turns, make and keep friends and regulate their emotions. According to National Center for Learning Disabilities, 75% of the kids suffering from local disability suffer from problems associated with social skills.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Besides, cognitive behavioral therapy is focused on helping the child understand how thoughts of a person affect one’s feelings and behavior. Above all these therapies, it is most essential that parents should handle their child, who is suffering from this disorder, with excessive care and patience.

North America and Europe leads the learning disability treatment market with respect to the medication of ADHD and number of special schools for learning disability children. The U.S. Department of Education has established the law by the name “The Individuals with Disabilities Education Act (IDEA)”, which provides services to learning, disable individuals through its programs. Foundation for people with learning disabilities has also been established in the U.K., which deals with the patient concerns, conduct surveys, awareness programs and research and development activities in context to learning disability. Asia-Pacific is growing faster for learning disability treatment market majorly due to increasing government and private sector initiatives to set up special schools and to spread awareness about the available medicines.

As for instance, Association of Learning Disabilities of India is working in association with Indian Association of Pediatrics, to improve the conditions of special schools and to spread awareness about the medications available. The major market players which manufacture ADHD medications for learning disability treatment include Pfizer, Inc., Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG and Shire Plc.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

    North America
    Asia Pacific
    Europe
    Rest of the World

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Monday, 9 January 2017

Primitive Neuroectodermal Tumors Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014-2020

ResearchMoz added Latest Research Report titled " Primitive Neuroectodermal Tumors Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020 " to it's Large Report database.

Primitive neuroectodermal tumors (PNETs) are a cancerous growth associated with the neural crest cells. Neural crest cells are embryonic cells migrates and transform into various cell types within the embryo during the formation of the neural tube. The tumors affecting of these cells are small round cells which are neuroectodermal origin, extremely malignant in nature and affect soft tissue organs and bones. Primitive neuroectodermal tumors on the basis of their origin categorized into three major classes such as CNS PNETs affecting central nervous system (CNS), neuroblastoma affecting autonomous nervous system (ANS) and peripheral PNETs derived from tissues other that CNS and ANS. These tumors generally affect the people within the age group of 5 to 25 years. These types of tumors are generally diagnosed by physical examination whereas computerized tomography scan and magnetic resonance imaging (MRI) can act as confirmatory tests. The treatment of PNETs depends on various factors such as type of PNET, position and size of tumors, age and general health of patient and nature of tumors.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=220223

Primitive neuroectodermal tumors are generally grouped in the Ewing family of tumors because of their resembling characters. According to article published by United States based Dana-Farber Cancer Institute, the annual incidence in the United States is 2.1 cases per million children for Ewing family of tumors, which is the second most common malignant bone tumor. The cases of PNETs are spread widely across the various regions of the world, and these numbers are growing rapidly. All these facts represent increasing demand of the various treatment options for PNETs globally in near future. The heavy investment in research and development, suitable reimbursement conditions and growing incidences and prevalence may drive the growth of the market. On the other hand high cost involved in treatment and limited awareness may hinder the growth of the overall market.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Currently there are many research projects under study that are focused on developing specific treatment for primitive neuroectodermal tumors. United Stated bases Burzynski Research Institute in collaboration with National Cancer Institute (NCI) studying antineoplastons A10 and AS2-1 for the treatment of primitive neuroectodermal tumors in children, Japanese giant Daiichi Sankyo Inc. evaluating the usage of exatecan mesylate in treating patients with primitive neuroectodermal tumor, Children\'s Oncology Group studying efficacy of carboplatin administered along with radiation and isotretinoin as a pro-apoptotic agent in PNET patients. Along with this, University of Florida in collaboration with U.S. Department of Defense is developing vaccine immunotherapy for primitive neuroectodermal tumor.

Primitive neuroectodermal tumors treatment market can be segmented according to different categories such as regional geography and available treatment options. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region will have highest contribution in terms of value because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances. Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. The market can also be segmented according to classes of drugs used for treatment such alkylating agents, platinum-based antineoplastic agents, topoisomerase inhibitor and others.

Currently many established players in pharmaceuticals and biotechnology market catering varied range of products in this market. Out of all companies, Daiichi Sankyo Inc., Novartis, Bristol Myers Squibb and Roche are some of the key players in this market.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

    North America
    Asia Pacific
    Europe
    Rest of the World

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Wednesday, 28 December 2016

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

ResearchMoz added Latest Research Report titled " Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline " to it's Large Report database.

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=903617

The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.

The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.

Scope

The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
Will generics continue to dominate treatment?
How do the elderly populations and their associated risk factors affect prevalence?
What effect will the patent expirations of currently branded therapies have on market value?

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 14
2.5.2 Automated Office Blood Pressure Measurement 14
2.5.3 Ambulatory Blood Pressure Monitoring 15
2.5.4 Home Blood Pressure Monitoring 15
2.5.5 Miscellaneous Methods 15
2.5.6 Diagnosis of Target Organ Damage 15
2.5.7 Diagnosis of Hypertension in Pregnancy 15
2.6 Prognosis 16
2.7 Disease Stage 17
2.8 Treatment Options 17
2.8.1 Treatment Algorithm 17
2.8.2 Pharmacological Treatment 18
2.8.3 Non-pharmacological Treatment 22

3 Marketed Products 24
3.1 Angiotensin II Receptor Antagonists 24
3.1.1 Losartan - Merck & Co 24
3.1.2 Olmesartan - Daiichi Sankyo 26
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo 27
3.1.4 Valsartan - Novartis 28

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG